Kura Oncology Gets U.S. Patent

Biopharmaceutical company Kura Oncology said it has been issued a U.S. patent for KO-947, its drug candidate targeting extracellular-signal-regulated kinases (ERK).

The new patent covers KO-947, and structurally-related compounds, as well as methods of using the compounds for the treatment of diseases including cancer. “We believe KO-947 holds much promise as a potential therapeutic, and we were pleased to have advanced it into Phase 1 clinical testing earlier this month,” said Troy Wilson President and CEO of Kura Oncology. “Issuance of this composition of matter patent is an important development for Kura and the program.”